The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin (Q43917059)

28 November 2017

title

The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin (English)

1 reference

28 November 2017

4

1 reference

28 November 2017

5

1 reference

28 November 2017

3

Ingrid B Borecki

1 reference

28 November 2017

Arash Rafii Tabrizi

1

1 reference

28 November 2017

Barbara A Zehnbauer

series ordinal

2

1 reference

28 November 2017

Bradley D Freeman

series ordinal

6

1 reference

28 November 2017

publication date

1 March 2002

1 reference

Journal of the American College of Surgeons

28 November 2017

published in

1 reference

28 November 2017

volume

194

1 reference

28 November 2017

issue

3

1 reference

28 November 2017

page(s)

267-273

1 reference

A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901163-2

7 January 2021

Inhibition of metastases by anticoagulants

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901163-2

7 January 2021

Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901163-2

7 January 2021

Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901163-2

7 January 2021

Management of anticoagulation before and after elective surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901163-2

7 January 2021

Warfarin anticoagulation in the perioperative period: is it safe?

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901163-2

7 January 2021

Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901163-2

7 January 2021

Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901163-2

7 January 2021

Stereoselective interaction between the R enantiomer of warfarin and cimetidine

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901163-2

7 January 2021

Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901163-2

7 January 2021

Allelic and functional variability of cytochrome P4502C9.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901163-2

7 January 2021

Genetic association between sensitivity to warfarin and expression of CYP2C9*3

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901163-2

7 January 2021

Cytochrome P450 polymorphisms are associated with reduced warfarin dose

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901163-2

7 January 2021

Interactions of warfarin with drugs and food

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901163-2

7 January 2021

Fluorescence energy transfer detection as a homogeneous DNA diagnostic method

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901163-2

7 January 2021

Homogeneous genotyping assays for single nucleotide polymorphisms with fluorescence resonance energy transfer detection

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901163-2

7 January 2021

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901163-2

7 January 2021

Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0.

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901163-2

7 January 2021

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

1 reference

https://api.crossref.org/works/10.1016%2FS1072-7515%2801%2901163-2

7 January 2021

10.1016/S1072-7515(01)01163-2

Identifiers

DOI

1 reference

28 November 2017

1 reference